Drugs - Real World Outcomes

Patient Satisfaction with High-Efficacy Therapies in Multiple Sclerosis: The Role of Administration Route and Shared Decision-Making

Francesco Pastore, Emanuela Domenicone, Patrizia DellOro, Charlotte Lefort

Corresponding author Francesco Pastore,
Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J)
University of Bari Aldo Moro,
Piazza Giulio Cesare, 11, 70121, Bari
e-mail: Francesco.pastore@uniba.it
ORCID 0000-0001-5491-2759

Online Resource 2. *Domains, items, response scales, and scoring methods of the questionnaire used to assess patients' experiences with multiple sclerosis therapy.*

Domain (Score)	Items	Response scale	Scoring method
Temporal and Organizational Burden of Therapy (Domain I)	1. How difficult is it to continue the multiple sclerosis therapy you are currently following? 2. Would you like a therapy that requires less administration time? 3. Would you like a therapy that requires fewer hospital visits? 4. Would you like improvements in the time spent during hospital stays? 5. Do you think that the time required for therapy management and monitoring has forced you to make personal sacrifices?	1 = not at all to 7 = very much	Mean of items
Perceived Impact of Therapy (Domain II)	6. The impact of therapy on your daily activities. 7. The time dedicated to therapy management. 8. The impact of therapy on your social life (family, relationships).	1 = extremely positive to 7 = extremely negative	Mean of items

Domain (Score)	Items	Response scale	Scoring method
	9. The impact of therapy on your quality of life. 10. The effort/burden required to follow therapy.		
Therapy Administration Experience (Domain III) Since you started your current therapy, how would you rate your experience with the following aspects?	11. The mode of administration. 12. The frequency of administration. 13. The speed of administration. 14. The difficulty in finding the vein/injection site. 15. The pain caused by injection. 16. The duration of drug administration. 17. The need for premedication. 18. The fact that the therapy cannot be taken at home. 19. The fact that you cannot inject yourself and must depend on a healthcare professional.	1 = extremely positive to 7 = extremely negative	Mean of items
Decision-Making Involvement Experience (Domain IV)	20. How involved did you feel by your neurologist in the choice of your current therapy? 21. How involved did you feel by your neurologist in discussions about multiple sclerosis? 22. How involved did you feel by your neurologist in discussions about available therapies? 23. How involved did you feel by your neurologist in discussions about new therapeutic options? 24. How involved did you feel by your neurologist in discussions about alternative therapies with different modes of administration?	1 = not at all to 7 = very much	Mean of items

Domain (Score)	Items	Response scale	Scoring method
	25. How involved did you feel by your neurologist in discussions about new therapies/treatments under experimentation?		
	26. How involved did you feel by your neurologist in discussions about practical lifestyle recommendations?		
	27. How involved did you feel by your neurologist in discussions about patients' rights (legal, bureaucratic, protections)?		